Short Interest in Profusa, Inc. (NASDAQ:PFSA) Expands By 90.3%

Profusa, Inc. (NASDAQ:PFSA) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 234,995 shares, an increase of 90.3% from the June 15th total of 123,461 shares. Based on an average daily trading volume, of 13,939,399 shares, the days-to-cover ratio is currently 0.0 days. Currently, 127.0% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of analysts have recently commented on PFSA shares. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Profusa Trading Down 1.6%

PFSA stock traded down $0.03 during trading on Thursday, reaching $1.86. The stock had a trading volume of 88,107 shares, compared to its average volume of 163,772. Profusa has a 52 week low of $1.80 and a 52 week high of $4,162.50. The firm has a market cap of $345,960.00, a PE ratio of -0.00 and a beta of 0.46. The stock’s 50 day moving average is $6.48 and its two-hundred day moving average is $51.95.

Profusa (NASDAQ:PFSA) last issued its quarterly earnings data on Wednesday, April 15th. The company reported $2,231.25 earnings per share for the quarter.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.